RDY Stock — Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited (RDY)

Updated October 16, 2026.

RDY is a Stock. its distribution rate is 0.64%, its trailing-12-month yield is 1.13%. Dividend Vision Distribution Safety Score™ is 59/100 (Caution). Total return is 1718.3% over the past 25.5 years, 785.8 points ahead of SPY at 932.5%.

Dr. Reddy's Laboratories Limited is an integrated pharmaceutical company headquartered in India that manufactures and markets generic and branded prescription drugs, over-the-counter medicines, biologics, and active pharmaceutical ingredients across North America, Europe, India, Russia, and other markets. The company operates a modest current distribution rate with annual distributions. The business appeals to income investors seeking pharmaceutical sector exposure with international diversification, though the modest yield may be of secondary importance to potential capital appreciation.

RDY performance versus SPY

Price and return data through 2026-10-16.

Total return is 1718.3% over the past 25.5 years, 785.8 points ahead of SPY at 932.5%. Over the past year its total return — price change plus distributions reinvested — is -7.2%. Its deepest 1-year drawdown was 25.8%.

RDY key facts

Distribution Safety Score™

59 · Caution

Safety-Adjusted Yield

0.38%

Asset type

Stock

Asset class

Equity

Inception date

04/11/2001

Distribution rate

0.64%

Distribution frequency

Annual

Trailing yield

1.13%

5-year average yield

0.65

Last close

$13.07 (as of 2026-10-16)

Market cap

$10,887,161,329

Average volume

2794062.0

Dividend

$0.08341

Ex-dividend date

07/24/2026

Payment date

08/05/2026

Beta

0.25

Payout ratio

35.2%

P/E ratio

29.04

Forward P/E

27.027

EPS

$0.45

How Dividend Vision calculates yield and returns

Distribution rate (0.64%) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (1.13%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RDY risks and drawbacks

RDY's current distribution rate is moderate, not a high-yield payout — the strategy is dividend quality more than maximum income. Payments are annual, so cash flow is lumpy versus a monthly fund. The deepest 1-year drawdown on record here is 25.8%.

Who may consider RDY — and who may not

It is a weaker fit for investors who need monthly cash flow (RDY pays annual); investors hunting double-digit covered-call yields. This is educational context, not a recommendation to buy or sell.

More on RDY

• All tickers starting with R

Tagged: Pharmaceutical, Dividend.

Frequently asked questions